Related references
Note: Only part of the references are listed.Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
John Pagel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Pierre Sesques et al.
BLOOD (2017)
EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features
Yang Liu et al.
HUMAN PATHOLOGY (2017)
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Dorothy Brach et al.
MOLECULAR CANCER THERAPEUTICS (2017)
EZH2 in normal hematopoiesis and hematological malignancies
Laurie Herviou et al.
ONCOTARGET (2016)
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas
Hans G. Drexler et al.
LEUKEMIA & LYMPHOMA (2016)
Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine
Ruifang Sun et al.
MODERN PATHOLOGY (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Polycomb genes, miRNA, and their deregulation in B-cell malignancies
Gang Greg Wang et al.
BLOOD (2015)
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention
Chen Shen et al.
CURRENT OPINION IN ONCOLOGY (2015)
Targeting EZH2 for Cancer Therapy: Progress and Perspective
Chi Han Li et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2015)
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™
Feng Sun et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
H. Horn et al.
LEUKEMIA (2015)
DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis
Mingquan Sha et al.
ACTA PHARMACEUTICA SINICA B (2015)
A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma
Itziar Salaverria et al.
BLOOD (2014)
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation
William D. Bradley et al.
CHEMISTRY & BIOLOGY (2014)
EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma
Shu-Bin Gao et al.
MOLECULAR CANCER RESEARCH (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells
Shigeki Nakagawa et al.
ONCOLOGY REPORTS (2014)
3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells
Nicolas Girard et al.
PLOS ONE (2014)
Regulation and Role of EZH2 in Cancer
Hirohito Yamaguchi et al.
CANCER RESEARCH AND TREATMENT (2014)
An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
Kyle D. Konze et al.
ACS CHEMICAL BIOLOGY (2013)
EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
Junli Yan et al.
BLOOD (2013)
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Csaba Boedoer et al.
BLOOD (2013)
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
Heike Horn et al.
BLOOD (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
U-2932: two clones in one cell line, a tool for the study of clonal evolution
H. Quentmeier et al.
LEUKEMIA (2013)
The role of EZH2 in tumour progression
C-J Chang et al.
BRITISH JOURNAL OF CANCER (2012)
Inner workings and regulatory inputs that control Polycomb repressive complex 2
M. Maggie O'Meara et al.
CHROMOSOMA (2012)
Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2012)
A687V EZH2 is a gain-of-function mutation found in lymphoma patients
Christina R. Majer et al.
FEBS LETTERS (2012)
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells
Junko Kikuchi et al.
LUNG CANCER (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson et al.
NATURE CHEMICAL BIOLOGY (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
Levi A. Garraway et al.
CANCER DISCOVERY (2012)
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Damian B. Yap et al.
BLOOD (2011)
The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML
Jianbiao Zhou et al.
BLOOD (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Warren Fiskus et al.
BLOOD (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
Raphael Margueron et al.
MOLECULAR CELL (2008)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast
IM Bachmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
AP Bracken et al.
EMBO JOURNAL (2003)
The polycomb group protein EZH2 is involved in progression of prostate cancer
S Varambally et al.
NATURE (2002)
Share Paper
